Validation of a panel of biomarkers to predict preterm birth in asymptomatic women
Preterm Birth Prediction In Asymptomatic Women At Mid-Gestation Using A Panel Of Novel Protein Biomarkers: The Prediction Of Preterm Labor (Ppetal) Study
The analysis and validation of Carmentix’s biomarkers have been published in the American Journal of Obstetrics & Gynecology MFM. Here, the authors have validated the biological and clinical significance of a panel of biomarkers that identified asymptomatic women (16 to 24 weeks of gestation) at risk of preterm birth with high sensitivity and specificity. The early prediction of women at risk of preterm birth will allow for better clinical management and preventative treatments.
To find out more: https://www.sciencedirect.com/science/article/pii/S2589933319301247